Skip to main content

Table 2 Crude and Adjusted Prostate Cancer Risk Estimates

From: Urinary estrogen metabolites and prostate cancer: a case-control study and meta-analysis

    Cs/Coa Crude ORb 95% CIc Adjusted ORd 95% CIc
2OHE1
  1st tertile ≤ 0.21 10/37 1 - - -
  2nd tertile 0.21 - 2.26 9/37 0.90 0.33 -2.47 0.90 0.32-2.46
  3rd tertile > 2.26 7/36 0.72 0.25 -2.10 0.69 0.23-2.03
  trend    0.85 0.50-1.44 0.83 0.49-1.42
  P for trend    0.55   0.50  
16OHE1
  1st tertile ≤ 61.84 7/37 1 - - -
  2nd tertile 61.84 - 158.74 7/37 1.00 0.32 - 3.13 1.00 0.32-3.13
  3rd tertile >158.74 12/36 1.76 0.62 - 4.98 1.73 0.58-5.14
  trend    1.35 0.80-2.30 1.33 0.76-2.33
  P for trend    0.26   0.31  
2OHE1/16OHE1
  1st tertile ≤ 0,31 11/37 1 -   -
  2nd tertile 0.31-1.64 9/37 0.82 0.30-2.21 0.80 0.30-2.17
  3rd tertile > 1.64 6/36 0.56 0.19 - 1.68 0.57 0.19-1.71
  trend    0.75 0.44-1.29 0.76 0.44-1.30
  P for trend    0.30   0.31  
  1. a matched on age, race and recruitment period
  2. b odds ratio; c95% confidence interval; dadjusted for age